Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 102.21 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Ligand Offers $15 Million to Acquire Assets of Novan, Inc. July 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection July 17, 2023 From Novan, Inc. Via GlobeNewswire 3 Stocks That Smart Investors Should Be Flocking to Now May 30, 2023 Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. Via InvestorPlace Recap: Ligand Pharmaceuticals Q1 Earnings May 04, 2023 Via Benzinga Ligand Pharmaceuticals Earnings Preview February 21, 2023 Via Benzinga Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know December 23, 2022 Via Benzinga Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial May 16, 2023 Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in Via Benzinga Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) May 16, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports First Quarter 2023 Financial Results May 04, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 April 24, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Fourth Quarter and Full Year 2022 Financial Results February 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment February 21, 2023 Via Benzinga Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Earnings Scheduled For February 22, 2023 February 22, 2023 Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. Via Benzinga Ligand to Report Fourth Quarter Financial Results on February 22 February 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More January 31, 2023 The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... Via Benzinga Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum January 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tesla To $175? Here Are 10 Other Price Target Changes For Friday December 23, 2022 Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... Via Benzinga Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says December 16, 2022 Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. Via Benzinga Ligand Pharma Issues Mixed Guidance For FY23 December 13, 2022 At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... Via Benzinga Ligand Provides Highlights from its Investor and Analyst Day Event December 13, 2022 From Ligand Pharmaceuticals Via Business Wire Ligand Pharmaceuticals Names Director Todd C. Davis as CEO December 05, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Hold Investor and Analyst Day on December 13 November 16, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Third Quarter 2022 Financial Results November 07, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Earnings Outlook For Ligand Pharmaceuticals November 04, 2022 Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 02, 2022 Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. Via Benzinga Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga Ligand Announces Completion of OmniAb Spin-Off November 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Distribution of OmniAb Complete and Business Combination Closed November 01, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Third Quarter Financial Results on November 7 October 26, 2022 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.